Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Addendum to "Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial"

  • Jean E Schoenen, Co-Director Headache Research Unit
Published October 01, 2015

Additional statistical analyses were performed on the outcome measures presented in Schoenen et al. [1] to account for covariates. A rank analysis of covariance was performed, using the non-parametric Spearman's rank correlation coefficient. [2] The results showed that age and disease duration does not impact on study outcomes. However, the number of migraine days during the 1-month baseline period had an influence on the decrease in migraine days during the 3rd month of treatment. In the original publication, the difference between verum and sham groups in the reduction of migraine days (respectively -29.7% and -4.9%) just missed the significance threshold (p=0.054). [1] However, when baseline migraine days are considered as a covariate, this difference becomes significant (p=0.044). This analysis therefore suggests that the beneficial effect of Cefaly for migraine prevention might be greater in patients with more frequent migraines, which is of interest for clinical practice.

1. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013; 80:697-704.

2. Stokes ME, Davis CS, Koch GG. Categorical Data Using the SAS System, 2nd ed. Cary, NC: SAS Institute Inc.; 2000.

For disclosures, please contact the editorial office at journal@neurology.org.

Editor's Note: An update related to this letter will be published in an upcoming print issue.

Navigate back to article

Neurology: 93 (24)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2019 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise